Progenics Pharma (PGNX) Misses Q2 EPS by 3c; Sees AZEDRA NDA in August
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Price: $4.10 --0%
Financial Fact:
General and administrative: 7.22M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
General and administrative: 7.22M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Progenics Pharma (NASDAQ: PGNX) reported Q2 EPS of ($0.24), $0.03 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $3.68 million.
NDA (New Drug Application) for AZEDRA® Expected to be Submitted to U.S. Food and Drug Administration (FDA) in August 2017
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Zymeworks ZW191 shows 64.5% response rate in ovarian cancer trial
- Cumberland Pharmaceuticals reports Phase 2a ifetroban trial results
Create E-mail Alert Related Categories
Earnings, FDA, GuidanceRelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
